For this supplement, the expert faculty provided detailed perspectives on the evolving role of isatuximab in the multiple myeloma treatment paradigm, including their point of view on recent data from the phase 3 GMMG HD7 study and the cost implications for the use of isatuximab-based regimens in myeloma, along with their overall impressions of the current costs of myeloma care and treatment.
Supported through funding from
